Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 1, 2014

BioPharm International

  • BioPharm International-04-01-2014
  • Volume 27
  • Issue 4

High-Performance Separation-Electrospray Ionization System

High-Performance Separation-Electrospray Ionization System

AB Sciex introduces the CESI 8000 System for Biologics Characterization, a high-performance separation-electrospray ionization system for mass spectrometry. CESI combines capillary electrophoresis (CE) and electrospray ionization (CESI). This new front-end CESI technology from the company’s SCIEX Separations business can be integrated with the AB Sciex TripleTOF 5600+ MS system.

The CESI 8000 provides improved results compared to dual-method liquid chromatography/mass spectrometry-based approaches.  From a single digest and run, users of CESI-MS gain identity and purity information with 100% coverage in a peptide map, heterogeneity information with ultrasensitive glycopeptide quantitation, and stability information identifying, deamidation, cyclization, and oxidation.

According to the company, CESI technology is designed to improve biophysicochemical characterization and guide the development of biologics-based therapeutics.  Specifically, CESI-MS serves to improve ionization efficiency and reduce ion suppression.

AB Sciexa


Related to this article

The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.